Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
No reports describe high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell transplantation (auto-PBSCT) in pediatric patients with neuroblastoma and end-stage renal disease. Here, we report the case of a patient with high-risk neuroblastoma who developed anuria during treatment. HDCT with auto-PBSCT under hemodialysis, with strict attention to the ultrafiltration volume and dose modification of alkylating agents, was performed. Although the first auto-PBSCT led to engraftment failure, the second auto-PBSCT resulted in successful myeloid engraftment 8 months after anuria. This case demonstrated that HDCT with auto-PBSCT can be safely performed in children with renal failure under hemodialysis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPH.0000000000002090 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparing Two Approaches to Identify Individuals with Severe Asthma in United States Claims Data.
Pharmacoepidemiol Drug Saf
September 2025
Sanofi, Cambridge, Massachusetts, USA.
Purpose: Given the increased likelihood for individuals with severe asthma to experience comorbidities, disease complications, emergency room visits, and hospitalizations, the ability to stratify asthma populations on severity is often important. Although pharmacoepidemiologic studies using administrative healthcare databases sometimes categorize asthma severity, there is no consensus on an approach.
Methods: Individuals with asthma (≥ 2 ICD-10-CM diagnosis codes J45) aged ≥ 6 years were identified in Optum's de-identified Clinformatics Data Mart Database between January 2017 and November 2023.
Eosinophilic granulomatosis with polyangiitis complicated with bullous pemphigoid.
BMJ Case Rep
September 2025
Division of Neurology, Department of Internal Medicine, Nihon University School of Medicine, Itabashi, Tokyo, Japan.
Eosinophilic granulomatosis with polyangiitis (EGPA) and bullous pemphigoid (BP) are both autoimmune diseases characterised by eosinophilic involvement. Coexistence of the two diseases is rare, and confirmatory immunological analyses for BP are lacking in such cases. Here, we report a male in his 80s diagnosed with EGPA 5 years previously who developed numbness and tense blisters but showed no peripheral eosinophilia.
View Article and Find Full Text PDFEvaluating the impact of relative dose intensity on efficacy of trastuzumab deruxtecan for metastatic breast cancer in the real-world clinical setting.
Ann Acad Med Singap
August 2025
Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
Introduction: Trastuzumab deruxtecan (T-DXd) has revolutionised treatment for metastatic breast cancer (MBC). While effective, its high cost and toxicities, such as fatigue and nausea, pose challenges.
Method: Medical records from the Joint Breast Cancer Registry in Singapore were used to study MBC patients treated with T-DXd (February 2021-June 2024).
Case Report: Effective methotrexate removal by combined hemodialysis and polymeric resin hemoadsorption.
Front Nephrol
August 2025
Department of Nephrology, Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal.
Background: High-dose methotrexate (HDMTX) is central to treating primary central nervous system lymphoma but carries a risk of acute kidney injury (AKI), which can delay methotrexate (MTX) clearance and increase toxicity. Glucarpidase is the treatment of choice for MTX toxicity, but limited access in many countries may necessitate alternatives. We present the first reported adult case of combined high-flux hemodialysis (HFHD) and HA230 hemoadsorption for MTX clearance.
View Article and Find Full Text PDF[Progress on biologic therapies for severe asthma].
Zhonghua Jie He He Hu Xi Za Zhi
September 2025
Department of Allergy and Clinical Immunology, the First Affiliated Hospital of Guangzhou Medical University, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, National Center for Respiratory Medicine, G
Biologics play a critical role in the treatment of severe bronchial asthma. Both () and in our country recommend currently approved biologics as add-on therapies for patients whose symptoms remain uncontrolled despite high dose maintenance ICS-LABA treatments. The approved biologics include Omalizumab, Mepolizumab, Benralizumab, Reslizumab, Dupilumab, and Tezepelumab.
View Article and Find Full Text PDF